Cryopreservation of buffy coat–derived platelet concentrates photochemically treated with amotosalen and UVA light

Meinke, Stephan; Wikman, Agneta; Gryfelt, Gunilla; Hultenby, Kjell; Uhlin, Michael; Höglund, Petter; Sandgren, Per

doi:10.1111/trf.14905

Cited by 22 publications

(34 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It remains however to be demonstrated what a positive calcein stain then actually means and whether this "viable" tag implies that the platelet is functional. Other methods that have assessed "viability" in the context of cryopreservation research are extracellular lactate dehydrogenase activity [12], hypotonic stress response [13,14] and mitochondrial membrane potential [11,15] but there is no evidence that these are more appropriate than calcein staining for the "viability" outcome parameter.…”

Section: Platelet Viability and Recoverymentioning

confidence: 99%

Platelet Biochemistry and Morphology after Cryopreservation

Six

Compernolle

Feys

2020

IJMS

View full text Add to dashboard Cite

Platelet cryopreservation has been investigated for several decades as an alternative to room temperature storage of platelet concentrates. The use of dimethylsulfoxide as a cryoprotectant has improved platelet storage and cryopreserved concentrates can be kept at −80 °C for two years. Cryopreserved platelets can serve as emergency backup to support stock crises or to disburden difficult logistic areas like rural or military regions. Cryopreservation significantly influences platelet morphology, decreases platelet activation and severely abrogates platelet aggregation. Recent data indicate that cryopreserved platelets have a procoagulant phenotype because thrombin and fibrin formation kicks in earlier compared to room temperature stored platelets. This happens both in static and hydrodynamic conditions. In a clinical setting, low 1-h post transfusion recoveries of cryopreserved platelets represent fast clearance from circulation which may be explained by changes to the platelet GPIbα receptor. Cryopreservation splits the concentrate in two platelet subpopulations depending on GPIbα expression levels. Further research is needed to unravel its physiological importance. Proving clinical efficacy of cryopreserved platelets is difficult because of the heterogeneity of indications and the ambiguity of outcome measures. The procoagulant character of cryopreserved platelets has increased interest for use in trauma stressing the need for double-blinded randomized clinical trials in actively bleeding patients.

show abstract

Section: Platelet Viability and Recoverymentioning

confidence: 99%

Platelet Biochemistry and Morphology after Cryopreservation

Six

Compernolle

Feys

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Clot strength showed generally small non‐significant variations over storage time [all authors]. When PLT concentrates are pathogen inactivated, either with riboflavin or amotosalen and UV light, a lower clot strength can be observed . When poor storing PLTs with Ph < 6.0 were compared with good storing PLTs with pH > 6.6, significant differences in clot strength were observed on Day 12.…”

Section: Whole Blood Donations and Blood Componentsmentioning

confidence: 99%

“…However, others observed a significant and consistent increase in clot strength, using PLT concentrations ranging from 25-250 x 10 9 /l in diluted plasma [28]. The advantage of using a relative low PLT concentration of 100 x 10 9 /l to test PLT activity with thromboelastography is a test suspension with a minimum content of PLT concentrate storage medium and a maximum content of standard plasma, such as S/Dtreated plasma ( 56,58]. When poor storing PLTs with Ph < 6.0 were compared with good storing PLTs with pH > 6.6, significant differences in clot strength were observed on Day 12.…”

Section: Platelet Concentrates: Storage Lesion Of Fresh Plateletsmentioning

confidence: 99%

Thromboelastography as a tool to evaluate blood of healthy volunteers and blood component quality: a review

2019

View full text Add to dashboard Cite

Thromboelastography is a technique to evaluate the overall coagulation behaviour of blood and blood components. First, we evaluated the literature concerning the use of thromboelastography for characterizing coagulation behaviour of healthy volunteers, such as blood donors. Overall coagulation is sensitive to gender, most likely caused by the difference in haematocrit and plasma content of male versus female blood. Smaller and less pronounced effects in thromboelastographic response are caused by differences in fibrinogen level or by use of oral contraceptives. Short‐term hypercoagulable effects are observed after smoking or blood donation, while small effects of non‐steroidal anti‐inflammatory drugs on platelets are also present. Second, in whole blood donations, the thromboelastographic variables are also sensitive to storage time and temperature, but are less sensitive to levels of clotting factors. Platelet count and quality have little influence on thromboelastographic variables, and differences are mainly observed at counts <100x109/l, after extended storage time of platelet concentrates or storage under specific conditions, including freezing. Thromboelastographic profiles of plasma samples are mainly affected by residual cell counts, microparticles and fibrinogen levels, and less by levels of clotting factors. Taken together, publications have shown that as an overall clotting test, thromboelastography may support optimization of blood component preparation and storage with regard to temperature, time and secondary and tertiary treatments. Minimal deviations of in vitro quality are most reliable demonstrated when an appropriate assay is chosen.

show abstract

“…However, previous data demonstrate that PLT components meeting the specifications used in this study are suitable for UVC‐PI treatment followed by conventional storage at 20 to 24°C. 15 The results are also in line with recent reports of INTERCEPT‐treated CPPs, which demonstrate minimal alterations to the CPP phenotype . Additionally, if the rationale for PI treating PLTs is to improve product safety, then PI treatment of the plasma used as the resuspension medium should also be considered.…”

Section: Discussionmentioning

confidence: 99%

“…Pathogen inactivation treatment of PLT products before cryopreservation is a relatively new concept. One study has investigated the treatment of PLTs with the INTERCEPT System before cryopreservation, revealing a similar in vitro phenotype and functionality compared to untreated CPPs after thawing . Thus, combining PI treatment and cryopreservation appears to be feasible.…”

mentioning

confidence: 99%

Cryopreservation of UVC pathogen‐inactivated platelets

et al. 2019

View full text Add to dashboard Cite

BACKGROUND Extending the platelet (PLT) shelf life and enhancing product safety may be achieved by combining cryopreservation and pathogen inactivation (PI). Although studied individually, limited investigations into combining these treatments has been performed. The aim of this study was to investigate the effect of PI treating PLTs before cryopreservation on in vitro PLT quality and function. STUDY DESIGN AND METHODS ABO‐matched buffy coat–derived PLTs in PLT additive solution (SSP+; Macopharma) were pooled and split to form matched pairs (n = 8). One unit remained untreated and the other was treated with the THERAFLEX UV‐Platelets System (UVC; Macopharma). For cryopreservation, 5% to 6% dimethyl sulfoxide was added to the PLTs, and they were frozen at −80°C. After being thawed, untreated cryopreserved PLTs (CPPs) and UVC‐treated CPPs (UVC‐CPPs) were resuspended in plasma. In vitro quality was assessed immediately after thawing and after 24 hours of room temperature storage. RESULTS UVC‐CPPs had lower in vitro recovery compared to CPPs. By flow cytometry, PLTs demonstrated a similar abundance of GPIX (CD42a), GPIIb (CD41a), and GPIbα (CD42b‐HIP1), while the activation of GPIIb/IIIa (PAC‐1) was increased in UVC‐CPPs compared to CPPs. UVC‐CPPs demonstrated greater phosphatidylserine exposure (annexin V) and microparticle shedding but similar P‐selectin (CD62P) abundance compared to CPPs. UVC‐CPPs displayed similar functionality to CPPs when assessed using aggregometry, thromboelastography, and thrombin generation. CONCLUSIONS This study demonstrates the feasibility of cryopreserving UVC‐PI–treated PLT products. UVC‐PI treatment may increase the susceptibility of PLTs to damage caused during cryopreservation, but this is more pronounced during postthaw storage at room temperature.

show abstract

Cryopreservation of buffy coat–derived platelet concentrates photochemically treated with amotosalen and UVA light

Cited by 22 publications

References 42 publications

Platelet Biochemistry and Morphology after Cryopreservation

Platelet Biochemistry and Morphology after Cryopreservation

Thromboelastography as a tool to evaluate blood of healthy volunteers and blood component quality: a review

Cryopreservation of UVC pathogen‐inactivated platelets

Contact Info

Product

Resources

About